These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29681367)

  • 21. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
    J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
    Fanikos J; Burnett AE; Mahan CE; Dobesh PP
    Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study.
    Lehto M; Luojus A; Halminen O; Haukka J; Putaala J; Linna M; Mustonen P; Kinnunen J; Lehtonen O; Teppo K; Tiili P; Kouki E; Itäinen-Strömberg S; Niemi M; Aro AL; Hartikainen J; Airaksinen KEJ;
    Ann Med; 2024 Dec; 56(1):2364825. PubMed ID: 38873855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
    Norby FL; Alonso A
    J Comp Eff Res; 2017 Sep; 6(6):549-560. PubMed ID: 28737102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
    Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
    Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
    Alamneh EA; Chalmers L; Bereznicki LR
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
    Chan YH; Yeh YH; See LC; Wang CL; Chang SH; Lee HF; Wu LS; Tu HT; Kuo CT
    J Am Coll Cardiol; 2016 Nov; 68(21):2272-2283. PubMed ID: 27884245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
    Mugnai G; de Asmundis C; Iacopino S; Stroker E; Longobardi M; De Regibus V; Coutino-Moreno HE; Takarada K; Choudhury R; Abugattas de Torres JP; Storti C; Brugada P; Chierchia GB
    Am J Cardiol; 2017 Jul; 120(2):223-229. PubMed ID: 28532773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
    Mueller T; Alvarez-Madrazo S; Robertson C; Wu O; Bennie M
    Br J Clin Pharmacol; 2019 Feb; 85(2):422-431. PubMed ID: 30423191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evidence of novel oral anticoagulants (NOAC)].
    Kitazono T
    Rinsho Shinkeigaku; 2013; 53(11):992-3. PubMed ID: 24291856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
    Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
    Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
    Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
    Schäfer A; Flierl U; Berliner D; Bauersachs J
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):555-568. PubMed ID: 32350792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.